Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 60732 in healthy male volunteers
NCT02244203Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 60732 in thromboembolism, sponsored by Boehringer Ingelheim. Primary endpoint: Number of patients with clinically relevant changes in vital signs at 21 days. Started Feb 2009; status: completed.
02
Drugs
BI 60732
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02244203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244203.